Select Topic:
Browse by Series:

Later Lines of Therapy for Metastatic Colorectal Cancer

Insights From: Tanios Bekaii-Saab, MD, Mayo Clinic; Johanna C. Bendell, MD, Sarah Cannon Research Institute
Published: Tuesday, Nov 13, 2018



Transcript:

Tanios Bekaii-Saab, MD: Almost 90% or more of patients who progressed through first-line therapy will make it to the second line. Second-line options will depend on what you
Slider Left
Slider Right


Transcript:

Tanios Bekaii-Saab, MD: Almost 90% or more of patients who progressed through first-line therapy will make it to the second line. Second-line options will depend on what you
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x